Home Cart Sign in  
Chemical Structure| 1143-70-0 Chemical Structure| 1143-70-0

Structure of Urolithin A
CAS No.: 1143-70-0

Chemical Structure| 1143-70-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Urolithin A is a metabolite of ellagitannin with antiproliferative and antioxidant properties. It can cross the blood brain barrier, and may have neuroprotective effects against Alzheimer’s Disease. Urolithin A has been shown to stimulate mitophagy and improve muscle function in aged animals15 and in models of muscular dystrophy,16 while also being safe, bioavailable, and able to induce mitochondrial gene expression in older adults.

Synonyms: 2',7-Dihydroxy-3,4-benzocoumarin; 3,8-Dihydroxy Urolithin

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Heyns, Ingrid Marie ; Ganugula, Raghu ; Kumar, MNV Ravi ; Arora, Meenakshi ;

Abstract: In the past decade, liquid chromatography−mass spectrometry (LC-MS/MS) has become pivotal in clinical diagnosis, drug discovery, and bioanalytical science due to its high sensitivity and rapid analysis. We have developed an ultrasensitive and robust LC-MS/MS method for the simultaneous detection and quantification of cyclosporine A (CsA) and (UA) employing (ASC) and (NAR) as internal standards (ISTDs). The method was validated for clinical use, revealing interspecies differences between human plasma and other mammals (e.g., mouse, rat, feline, canine, and bovine serum). Validation parameters, including accuracy, precision, limits of quantification, specificity, selectivity, carryover, linearity, stability, and recovery, met acceptable ICH standards. Linear regression across the full calibration range (1−250 ng/mL for CsA and 0.5−125 ng/mL for UA) yielded an average R2 ≥ 0.999 in all mammal models. The method achieved a limit of quantification (LOQ) of 1−2.5 ng/mL across all model plasma samples with negligible carryover and demonstrated sample stability up to 96 h intra- and interday and 48 h for bovine serum. The method was successfully applied to quantify CsA and UA in canine samples following oral administration from a previous study. With a rapid run time of 6 min, this method offers high selectivity and precision, making it ideal for analyzing limited sample sizes and addressing regulatory challenges. The ability to simultaneously quantify CsA and UA has significant clinical potential for managing complex immuno-inflammatory diseases, enabling precise dose adjustments, and optimizing treatment outcomes.

Purchased from AmBeed:

Alternative Products

Product Details of Urolithin A

CAS No. :1143-70-0
Formula : C13H8O4
M.W : 228.20
SMILES Code : O=C1C2=CC(O)=CC=C2C3=C(O1)C=C(O)C=C3
Synonyms :
2',7-Dihydroxy-3,4-benzocoumarin; 3,8-Dihydroxy Urolithin
MDL No. :MFCD20275235
InChI Key :RIUPLDUFZCXCHM-UHFFFAOYSA-N
Pubchem ID :5488186

Safety of Urolithin A

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HEK293 APP-Swedish cells 30 μM To evaluate the effect of UA on Aβ42 expression in HEK293 APP-Swedish cells, it was found that UA decreased Aβ42 expression. Alzheimers Dement. 2024 Jun;20(6):4212-4233.
HMC3 human microglia cells 30 μM 48 hours To evaluate the effect of UA on IL-1β expression in HMC3 cells, it was found that UA significantly reduced IL-1β expression, and this effect was partially dependent on CTSZ. Alzheimers Dement. 2024 Jun;20(6):4212-4233.
SH-SY5Y cells 100 nM 24-48 h Urolithin A pretreatment significantly inhibited high glucose-induced mitochondrial calcium accumulation, indicating its regulatory effect on high glucose-induced mitochondrial calcium homeostasis. Cell Death Differ. 2021 Jan;28(1):184-202.
SH-SY5Y cells 100 nM 48 h Urolithin A pretreatment significantly reduced high glucose-induced mtROS levels, indicating its inhibitory effect on high glucose-induced oxidative stress. Cell Death Differ. 2021 Jan;28(1):184-202.
SH-SY5Y cells 100 nM 72 h Urolithin A significantly reduced high glucose-induced LDH release, indicating its protective effect against high glucose-induced cell damage. Cell Death Differ. 2021 Jan;28(1):184-202.
HEK293 APP-Swedish cells 30 μM 48 h To investigate the effect of Urolithin A on Aβ42 expression in HEK293 APP-Swedish cells, results showed that UA decreased Aβ42 expression. Alzheimers Dement. 2024 Jun;20(6):4212-4233.
HMC3 human microglia cells 30 μM 48 h To investigate the effect of Urolithin A on Aβ42-induced inflammatory response in HMC3 cells, results showed that UA significantly reduced IL-1β expression. Alzheimers Dement. 2024 Jun;20(6):4212-4233.
ARPE-19 cells 100 μM 24 h UA restored viability in SI-treated ARPE-19 cells and reduced 4-HNE levels, indicating that UA maintained proteostasis by restoring autophagic flux. Mol Neurodegener. 2024 Jun 18;19(1):49.
HepG2 cells 20 μM 24 h To validate the role of MUP1 in UA-mediated alleviation of alcohol-induced ER stress, results showed that knockdown of MUP1 attenuated the beneficial effects of UA on ER stress-related proteins. Gut Microbes. 2024 Jan-Dec;16(1):2367342.
BMDMs 5, 10, 25, 50 µM 24 h To observe the effect of UA on BMDMs cell activity and inflammatory factors, it was found that UA treatment inhibited CM stimulation-induced elevated mRNA expression of IL-6 and TNF-α and decreased extracellular secretion of IL-6. J Adv Res. 2025 Mar;69:125-138.
THP-1 5, 10, 25, 50 µM 24 h To observe the effect of UA on THP-1 cell activity and inflammatory factors, it was found that UA treatment inhibited CM stimulation-induced elevated mRNA expression of IL-6 and TNF-α and decreased extracellular secretion of IL-6. J Adv Res. 2025 Mar;69:125-138.
Th17 cells 5 µM 4 h URA significantly inhibited the differentiation of CD4+ T cells into Th17 cells, reduced IL-17 secretion, and decreased the expression of Th17-related genes. EBioMedicine. 2021 Feb;64:103227.
Bone marrow-derived dendritic cells (BM-DCs) 25 µM 18 h URA inhibited the activation of BM-DCs, reduced the expression of co-stimulatory molecules CD80, CD86, and MHCII, and suppressed the secretion of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α, while increasing the expression of anti-inflammatory cytokine IL-10. EBioMedicine. 2021 Feb;64:103227.
primary mouse cardiomyocytes 10 μg/mL 6 h To evaluate the protective effect of UA on LPS-induced cardiomyocyte injury, the results showed that UA significantly improved cell viability and alleviated LPS-induced cardiomyocyte injury. MedComm (2020). 2023 Dec 19;4(6):e459.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice APP/PS1 mice, 3xTgAD mice, 3xTgAD/Pol β+/− mice Oral gavage 200 mg/kg/day Once daily for 5 months To evaluate the effects of long-term UA treatment on cognitive function, olfactory function, synaptic function, Aβ and tau pathology, neuroinflammation, lysosomal function, and DNA damage in AD mice. The results showed that UA significantly improved learning, memory, and olfactory function in AD mice, reduced Aβ and tau pathologies, enhanced long-term potentiation, and induced mitophagy by increasing lysosomal functions. Alzheimers Dement. 2024 Jun;20(6):4212-4233.
Mice STZ-induced diabetic mouse model Intraperitoneal injection 2.5 mg/kg Once daily for 8 weeks Urolithin A injection significantly inhibited STZ-induced expression of APP, BACE1, and p-Tau, as well as Aβ deposition, indicating its protective effect against diabetes-associated Alzheimer's disease pathology. Cell Death Differ. 2021 Jan;28(1):184-202.
Mice APP/PS1 mice, 3xTgAD mice, 3xTgAD/Pol β+/− mice Oral gavage 200 mg/kg Once daily for 5 months To investigate the effect of long-term Urolithin A treatment on learning and memory in Alzheimer's disease mouse models, results showed that UA significantly improved learning and memory and reduced Aβ and tau pathologies. Alzheimers Dement. 2024 Jun;20(6):4212-4233.
Mice C57BL/6J wild-type mice Intraperitoneal injection 2.3 mg/kg Daily for 7 days UA alleviated SI-induced neurodegeneration and preserved visual function. UA restored autophagic flux and triggered PINK1/Parkin-dependent mitophagy. Mol Neurodegener. 2024 Jun 18;19(1):49.
C57BL/6J mice Chronic alcohol-induced liver disease model Oral gavage 200 mg/kg Daily for 14 weeks UA alleviated chronic alcohol-induced liver disease by modulating the gut-microbiota-liver axis, significantly improving alcohol-induced metabolic disorders and hepatic ER stress, and restoring gut microbiota dysbiosis. Gut Microbes. 2024 Jan-Dec;16(1):2367342.
BALB/c mice Breast cancer xenograft model Dietary administration 2 g/kg Two weeks To observe the effect of UA on the breast cancer xenograft model, it was found that UA treatment significantly reduced tumor size and decreased IL-6 levels in the tumor environment. J Adv Res. 2025 Mar;69:125-138.
C57BL/6 mice Experimental autoimmune encephalomyelitis (EAE) model Oral 25 mg/kg Daily administration until the end of the experiment (30 days) URA significantly alleviated the clinical symptoms of EAE mice, reduced inflammatory cell infiltration and demyelination in the central nervous system, and decreased the numbers of M1-type microglia and activated dendritic cells, while also reducing the infiltration of Th1/Th17 cells. EBioMedicine. 2021 Feb;64:103227.
C57BL/6 mice Severe acute pancreatitis-associated acute cardiac injury (SACI) model Intraperitoneal injection 30 mg/kg 1 hour before and 3 hours after modeling, lasting for 24 hours To investigate the cardioprotective effect of UA on SACI mice and its mechanisms, the results showed that UA significantly reduced serum levels of amylase, lipase, LDH, CK-MB, BNP, cTnT, cTnI, alleviated pathological damage to pancreatic and cardiac tissues, and reduced myocardial cell apoptosis and oxidative stress. MedComm (2020). 2023 Dec 19;4(6):e459.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.38mL

0.88mL

0.44mL

21.91mL

4.38mL

2.19mL

43.82mL

8.76mL

4.38mL

References

 

Historical Records

Categories